Forecast
Period
|
2026-2030
|
Market
Size (2024)
|
USD
11.07 Billion
|
CAGR
(2025-2030)
|
4.40%
|
Fastest
Growing Segment
|
Laser-based
Equipment
|
Largest
Market
|
North
America
|
Market
Size (2030)
|
USD 14.17
Billion
|
Market Overview
Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market was valued at USD 11.07 Billion in 2024 and is expected to reach USD 14.17 Billion by 2030 with a CAGR of 4.40% during the forecast period. Benign Prostatic Hyperplasia (BPH), also
known as an enlarged prostate, is a common condition that affects many men as
they age. It leads to urinary symptoms like frequent urination, weak urine
flow, and the feeling of incomplete emptying of the bladder. The global market
for BPH treatment equipment has been witnessing significant growth in recent
years due to the increasing prevalence of this condition and the continuous
development of innovative treatment options. BPH is a condition that primarily affects older men,
with the risk increasing with age. As the global population continues to age,
the prevalence of BPH is on the rise. In addition to age, factors such as
genetics and hormonal changes also play a role in the development of BPH. This
increasing prevalence of BPH has driven the demand for effective treatment
options, leading to the growth of the BPH treatment equipment market. Several
treatment modalities are available for BPH, ranging from medications to
minimally invasive procedures and surgical interventions. The choice of
treatment depends on the severity of the symptoms, the patient's overall
health, and their preferences. Alpha-blockers
and 5-alpha reductase inhibitors are commonly prescribed medications to manage
BPH symptoms. They help relax the prostate and reduce its size, alleviating
urinary symptoms. Procedures like
Transurethral Microwave Therapy (TUMT), Transurethral Needle Ablation (TUNA),
and Water Vapor Therapy (Rezūm) are gaining popularity. These procedures offer
effective relief with minimal downtime. Traditional
surgical options like Transurethral Resection of the Prostate (TURP) and
Holmium Laser Enucleation of the Prostate (HoLEP) are still widely used for
severe cases. These procedures involve removing excess prostate tissue to
relieve symptoms.
Key Market Drivers
Rising Aging Population
The
global healthcare landscape is witnessing a significant transformation as the
world's population continues to age. With a growing number of elderly individuals
comes an increased prevalence of age-related health conditions. One such
condition that is on the rise is Benign Prostatic Hyperplasia (BPH), a
non-cancerous enlargement of the prostate gland in men. The prevalence of BPH
is tightly linked to age, and as the aging population surges, so does the
demand for BPH treatment equipment. Benign
Prostatic Hyperplasia (BPH) is a common condition among men, especially as they
age. It involves the non-cancerous enlargement of the prostate gland, which
surrounds the urethra and can lead to a range of urinary symptoms. BPH can
cause problems such as frequent urination, urgency, weak urine flow, difficulty
starting and stopping urination, and even urinary retention.
The global
population is aging at an unprecedented rate. According to the United
Nations, the number of people aged 60 and above is expected to double by 2050,
reaching nearly 2.1 billion. As men age, their risk of developing BPH
significantly increases. The prevalence of BPH is estimated to be around 50% in
men over the age of 50, and it climbs to 90% for those over the age of 80. With
this surge in the aging population, the burden of BPH is set to rise
exponentially. With more
elderly men experiencing BPH-related symptoms, there is a growing need for
accurate diagnosis. This has led to a surge in demand for diagnostic equipment,
including ultrasound devices, uroflowmetry machines, and prostate-specific
antigen (PSA) tests. As awareness of
BPH and its treatment options increases, patients and healthcare providers are
leaning towards minimally invasive procedures like transurethral resection of
the prostate (TURP), laser therapy, and prostate stents. These procedures often
require advanced medical equipment and are preferred by aging patients looking
for quicker recovery times. Many countries
are investing in expanding their healthcare infrastructure to accommodate the
growing needs of an aging population. This includes acquiring the necessary BPH
treatment equipment, further fueling market growth. The
pharmaceutical industry is also actively engaged in developing new medications
for BPH management. These medications may not replace equipment but can
complement existing treatments and drive further interest in BPH diagnosis and
management.
Increasing Healthcare
Expenditure
The
global healthcare industry has been experiencing a remarkable surge in
healthcare expenditure over the past few years. This increased investment in
healthcare infrastructure, research and development, and patient care is
significantly impacting various medical markets, including the Benign Prostatic
Hyperplasia (BPH) treatment equipment market. Rising healthcare expenditure is accelerating the
development of advanced medical technologies, including minimally invasive BPH
treatment equipment. Procedures such as Transurethral Resection of the Prostate
(TURP), laser therapy, and prostate artery embolization are becoming more
sophisticated and less invasive. This attracts both patients and healthcare
providers, driving the demand for the latest BPH treatment equipment. According to Eurostat, Germany's healthcare spending reached USD 508.53 billion in 2022, the highest among EU countries, followed by France (USD 326.54 billion), Italy (USD 183.03 billion), and Spain (USD 136.23 billion). As healthcare investments rise in these countries, with Germany, France, and Austria allocating 12.6%, 11.9%, and 11.2% of their GDP respectively, there is greater demand for advanced medical technologies, including those for BPH treatment. This trend of increasing healthcare expenditure is not only prevalent in major economies but also in smaller nations like Belgium, Sweden, and Portugal, which are investing heavily in healthcare. Such growth in spending is fostering the development of cutting-edge medical devices, driving innovation and expansion in the BPH treatment equipment market. Conversely, countries with lower healthcare spending, such as Luxembourg, may see slower growth in this market, highlighting the key role that healthcare investment plays in market dynamics.
Increased
funding in the healthcare sector is allowing for extensive research and
development efforts. Researchers and medical equipment manufacturers are
investing in innovative solutions for BPH treatment. These advancements are
focused on improving treatment outcomes, reducing side effects, and enhancing
the overall patient experience. As
healthcare expenditure rises, there is greater access to quality healthcare
services for individuals suffering from BPH. Patients are more willing to seek
early diagnosis and treatment, resulting in a higher demand for BPH treatment
equipment. This also means that patients are increasingly willing to explore
different treatment options, including the use of state-of-the-art equipment.
Governments worldwide are
allocating significant resources to healthcare infrastructure and patient care.
They are encouraging the adoption of modern medical equipment in hospitals and
clinics. These initiatives not only lead to increased demand for BPH treatment
equipment but also contribute to more efficient and accessible healthcare. With
the growth in healthcare expenditure, the global BPH treatment equipment market
is expanding geographically. Emerging markets are witnessing a surge in the
adoption of advanced medical equipment, creating new opportunities for
manufacturers. The overall market is becoming more competitive and dynamic.

Download Free Sample Report
Key Market Challenges
Growing Prevalence of BPH
One
of the primary challenges faced by the BPH treatment equipment market is the
rapidly growing prevalence of BPH. As the global population continues to age,
the number of men suffering from BPH is expected to rise. This demographic
shift places pressure on manufacturers to develop more efficient and
cost-effective treatment options.
Technological Advancements
Advancements
in medical technology are a double-edged sword for the BPH treatment equipment
market. While cutting-edge technologies can provide more effective treatments,
they also require significant investments in research and development. Staying
at the forefront of innovation is a challenge for manufacturers, as they must
continually update their products to remain competitive.
Regulatory
Hurdles
The
medical equipment industry is heavily regulated to ensure patient safety and
product effectiveness. Obtaining regulatory approvals for BPH treatment
equipment can be a lengthy and expensive process. Manufacturers must navigate
complex regulatory frameworks in different countries, which can hinder market
entry and expansion.
Cost
of Treatment
Cost
considerations are a major challenge for both patients and healthcare
providers. BPH treatment equipment can be expensive, making it less accessible
to patients in some regions. Manufacturers must find ways to reduce production
costs and increase affordability without compromising the quality and
effectiveness of their products.
Limited
Reimbursement Policies
In
many countries, reimbursement policies for BPH treatment equipment are limited,
which can discourage patients from seeking treatment. This lack of financial
support can impact the market's growth potential and hinder patients' access to
necessary treatments. Manufacturers must work with healthcare authorities to
establish better reimbursement policies.
Competition
The
BPH treatment equipment market is highly competitive, with multiple players
vying for market share. New entrants must find ways to differentiate themselves
and offer unique solutions to stand out in the crowded market. Established
companies must continually innovate to maintain their position.
Patient
Awareness and Education
Many
patients are unaware of the available BPH treatment options or delay seeking
medical attention due to embarrassment or fear. Increasing patient awareness
and education is a significant challenge, as it requires collaboration between
manufacturers, healthcare professionals, and advocacy groups.
Global
Economic Uncertainty
Economic
downturns and global economic uncertainties can affect healthcare spending,
including investments in BPH treatment equipment. Manufacturers must adapt to
changing economic conditions and find ways to remain financially stable during
challenging times.
Key Market Trends
Technological Advancements
The
global healthcare industry has been witnessing a remarkable transformation,
driven by continuous technological advancements. One area where these advancements
are making a significant impact is the treatment of Benign Prostatic
Hyperplasia (BPH). BPH, a non-cancerous enlargement of the prostate gland that
affects millions of men worldwide, has seen a surge in innovative treatment
options thanks to cutting-edge medical equipment and procedures. The advent of
advanced medical equipment and surgical techniques has given rise to minimally
invasive procedures like transurethral resection of the prostate (TURP), laser
therapy, and microwave therapy. These procedures are less invasive, have
shorter recovery times, and result in fewer complications compared to
traditional surgical interventions. Robotic
surgery has made a significant impact on BPH treatment. Robotic systems like
the da Vinci Surgical System enable surgeons to perform highly precise and minimally
invasive procedures, reducing patient discomfort and recovery time.
In August 2024, EDAP announced the successful treatment of the first patients in its Phase I/II study evaluating the Focal One robotic High-Intensity Focused Ultrasound (HIFU) for treating Benign Prostatic Hyperplasia (BPH). Phase I of the trial aims to identify the optimal treatment parameters for Focal One robotic HIFU in BPH patients. The trial is being conducted at two clinical sites in France. The precise delivery of HIFU energy by the Focal One system has the potential to significantly improve BPH symptoms with minimal side effects, enabling a faster recovery and return to normal activities for a large number of patients. This advancement in non-invasive treatment technology is expected to drive the growth of the global BPH treatment equipment market, as it offers an innovative and efficient solution for managing BPH with fewer complications, meeting the rising demand for effective healthcare solutions. Technological advancements in pharmaceuticals have led to the development of
more effective medications for managing BPH symptoms. Alpha-blockers, 5-alpha
reductase inhibitors, and combination therapies have improved the
pharmacological approach to BPH treatment. Advanced
imaging technologies, such as multiparametric magnetic resonance imaging
(mpMRI), have enhanced the diagnosis and monitoring of BPH. These tools help
physicians make more accurate treatment decisions and improve patient outcomes. The integration of telemedicine and remote monitoring
technologies has improved patient access to healthcare services and allowed for
more effective post-treatment care and follow-up.
Segmental Insights
Type Insights
Based on type, the Laser-based Equipment emerged as the fastest growing segment in the global market for Benign Prostatic Hyperplasia (BPH) Treatment Equipment during the forecast period. Laser treatments for Benign Prostatic Hyperplasia (BPH), including Holmium Laser Enucleation of the Prostate (HoLEP) and Photoselective Vaporization of the Prostate (PVP), are gaining popularity due to their minimally invasive nature. These procedures require either small incisions or no incisions at all, resulting in less pain and quicker recovery times compared to traditional surgery. Laser technology enables precise targeting of prostate tissue, minimizing damage to surrounding areas and reducing complications, which contributes to better patient outcomes. Additionally, laser treatments tend to have fewer side effects, such as bleeding or incontinence, compared to more invasive procedures like prostatectomy. This makes them highly attractive to patients who prioritize faster recovery and minimal disruption to daily life. The growing preference for less invasive options has fueled the surge in demand for laser-based treatments, especially among those with moderate to severe BPH. Ongoing advancements in laser technology, such as improved fiber-optic delivery systems and more efficient equipment, are enhancing treatment effectiveness and accessibility. Together, these factors are driving significant growth in the laser-based equipment segment, positioning it as the fastest-growing area within the BPH treatment market, in response to the increasing demand for safe, effective, and minimally invasive solutions.
End User Insights
Based on end user, the Hospitals & Clinics emerged as the dominating segment in the global market for Benign Prostatic Hyperplasia (BPH) Treatment Equipment in 2024. Hospitals and clinics are well-equipped with the advanced infrastructure required to deliver complex BPH treatments, including laser-based and minimally invasive procedures. Their capability to offer comprehensive care from initial diagnosis to post-treatment recovery ensures they remain the primary choice for BPH treatment. A key factor driving their dominance is the high volume of patients seeking care for BPH, a condition that becomes increasingly common with age. These facilities have established specialized urology departments and are outfitted with the latest medical technologies, enabling them to provide a broad range of treatment options, such as advanced robotic systems, laser therapies, and High-Intensity Focused Ultrasound (HIFU) procedures. Furthermore, hospitals and clinics benefit from their ability to deliver multidisciplinary care, including not only the treatment itself but also essential follow-up services such as post-operative care, rehabilitation, and management of potential complications. This holistic approach to patient care makes hospitals and clinics an attractive option for both patients and healthcare providers, ensuring the continued growth and dominance of this segment in the BPH treatment market.

Download Free Sample Report
Regional Insights
Based on Region, North America emerged as the dominant region in the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market in 2024. North America benefits from a highly developed healthcare infrastructure, which facilitates the adoption of advanced medical technologies, including laser treatments, robotic systems, and HIFU. According to the Canadian Institute for Health Information, total healthcare spending in Canada is projected to reach USD 372 billion in 2024, or USD 9,054 per capita. The significant healthcare investments in countries like the U.S. and Canada enhance both public and private healthcare systems, ensuring greater access to innovative BPH treatment options. As noted by the Population Reference Bureau, the number of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase, with the share of this age group in the total population rising from 17% to 23%. This aging population, with a growing number of men seeking BPH treatments, fuels demand for advanced medical devices. The region also boasts a robust network of specialized medical centers, hospitals, and clinics capable of offering comprehensive care, from diagnosis through post-treatment follow-up, improving patient outcomes. Additionally, North America is home to leading manufacturers and research institutions dedicated to developing new and enhanced BPH treatment technologies, further driving market growth. Strong government support for healthcare innovation, coupled with high awareness and widespread healthcare access, solidifies North America's position as a dominant force in the global BPH treatment equipment market.
Recent Developments
- In
December 2024, Zenflow, a medical device company focused on developing a
minimally invasive solution for urinary obstruction caused by an enlarged
prostate or benign prostatic hyperplasia (BPH), announced the successful
completion of a USD 24 million Series C financing round. The round attracted
new investor Cook Medical, along with existing investors Invus Opportunities,
F-Prime Capital, Medical Technology Venture Partners, and others. The raised
capital will be used to support the company’s Pre-Market Approval (PMA)
submission and to prepare for the commercialization of its Spring System, a
minimally invasive treatment for patients experiencing severe symptoms from an
enlarged prostate, pending FDA approval.
- At
the December 2024 LSX World Congress in London, discussions emphasized the
growing need for out-of-hospital treatments, such as Thermobalancing therapy,
to enhance patient safety. Recent clinical research has confirmed the high
effectiveness and safety of Thermobalancing therapy and Dr. Allen’s Devices in
alleviating pain in chronic prostatitis patients. Notably, this non-surgical
treatment is the first to offer a preventive solution for prostate enlargement,
a common age-related condition known as benign prostatic hyperplasia (BPH). The
effectiveness of Dr. Allen's Device in treating chronic prostatitis and BPH is
detailed in the article, Innovative Thermobalancing therapy and Dr. Allen's
Device for the first time employ body energy to treat chronic prostatic
diseases effectively, published in the International Journal of Quality
Innovation.
- In
August 2024, The Apollo Prostate Institute introduced water vapor therapy in
South India as a treatment for enlarged prostate glands. Also referred to as
steam therapy, this procedure uses a disposable device and lasts up to 15
minutes, with patients typically receiving mild sedation or local anesthesia.
The treatment involves injecting 0.45 milliliters (ml) of steam at temperatures
ranging from 100-113°C into targeted areas of the prostate to address
obstruction and alleviate symptoms associated with benign prostatic hyperplasia
(BPH).
- In
March 2024, Olympus marked a significant achievement for its iTind device,
expanding patient access through contracts with the largest healthcare group
purchasing organizations (GPOs) in the United States. The iTind procedure, a
minimally invasive treatment for benign prostatic hyperplasia (BPH), is now
available through 13 GPO contracts across the country.
Key Market Players
- Urologix, LLC
- Olympus
Corporation
- Boston
Scientific Corporation
- Teleflex
Incorporated
- Zenflow Inc.
- Sonablate
Corporation
- Richard Wolf
Gmbh
- Karl Storz SE
- Terumo Medical
Corporation
By
Type
|
By
End user
|
By Region
|
- Laser-based
Equipment
- Microwave-based
Equipment
- Radiofrequency-based
Equipment
- Other
|
- Hospitals &
Clinics
- Ambulatory Care
Centers
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Benign Prostatic
Hyperplasia (BPH) Treatment Equipment Market has been segmented into the
following categories, in addition to the industry trends which have also been
detailed below:
- Benign Prostatic Hyperplasia (BPH) Treatment
Equipment Market, By
Type:
o Laser-based Equipment
o Microwave-based Equipment
o Radiofrequency-based Equipment
o Other
- Benign Prostatic Hyperplasia (BPH) Treatment
Equipment Market, By
End user:
o Hospitals & Clinics
o Ambulatory Care Centers
o Others
- Benign Prostatic Hyperplasia (BPH) Treatment
Equipment Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Benign
Prostatic Hyperplasia (BPH) Treatment Equipment Market.
Available Customizations:
Global Benign Prostatic Hyperplasia (BPH) Treatment
Equipment market report with the given market data, Tech Sci Research
offers customizations according to a company's specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Benign Prostatic Hyperplasia (BPH) Treatment
Equipment Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]